Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 4, 2001, Pages 361-369

  Tentori, L ^a   Portarena, I ^a   Vernole, P ^a   De Fabritiis, P ^a   Madaio, R ^a   Balduzzi, A ^a   Roy, R ^a   Bonmassar, E ^a   Graziani, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Base excision repair; Leukemic cells; Poly(ADPribose) polymerase inhibitors; Temozolomide

Indexed keywords

ALKYLATING AGENT; DACARBAZINE; DNA; DRUG DERIVATIVE; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TEMOZOLOMIDE; 3 AMINOBENZAMIDE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O METHYLGUANINE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; CLASTOGEN; CYTOTOXIC AGENT; DNA GLYCOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CELL DIVISION; CELL SURVIVAL; CHROMOSOME ABERRATION; DNA REPAIR; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; LEUKEMIA CELL LINE; NORTHERN BLOTTING; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; EXCISION REPAIR; GROWTH INHIBITION; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, NORTHERN; CELL DIVISION; CELL SURVIVAL; CHROMOSOME ABERRATIONS; DACARBAZINE; DNA; DNA REPAIR; DOWN-REGULATION; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 0034743378     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000248     Document Type: Article

References (36)

1. Potentiation of temozolomide-induced cytotoxicity: A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors
2. Cloning and expression in Escherichia coli of human cDNA encoding the DNA repair protein N-methylpurine-DNA glycosylase
3. 6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow
4. Involvement of poly(ADP-ribose) polymerase in base excision repair
5. 6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients
6. Involvement of the mismatch repair system in temozolomide-induced apoptosis
7. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer
8. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: Implications for treatment with alkylating agents
9. Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia: A pilot study
10. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy
11. Mutator phenotype in human hematopoietic neoplasms and its association with deletions disabling DNA repair genes and bcl-2 rearrangements
12. Eukaryotic mismatch repair: An update
13. Microsatellite instability in lymphoid leukemia and lymphoma cell lines but not in myeloid leukemia cell lines
14. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide
15. Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemic line tolerant to methylating agents
16. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and proficient colon cancer cells to methylating agents
17. Evaluation of temozolomide in a SCID mouse model of human B-cell preleukemia
18. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
19. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials
20. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme
21. MSH2 deficient mice are viable and susceptible to lymphoid tumours
22. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma
23. Distinct substrate reference of human and mouse N-methyl-purine-DNA glycosylases
24. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine
25. 6alkylguanine-DNA alkyltransferase deficient leukemia cell lines
26. 6alkylguanine-DNA alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide
27. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with an inhibitor of poly(ADP-ribose) polymerase
28. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibits induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds
29. Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells
30. 6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity
31. Induction of apoptosis by bleomycin in resting and cycling human lymphocytes
32. 6-benzylguanine/temozolomide combination: An evaluation in a human melanoma xenograft model
33. Life without DNA repair
34. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
35. The food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine activates S-phase checkpoint and apoptosis, and induces gene mutation in human lymphoblastoid TK6 cells
36. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia